Analysis of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes.
Coppola, Giuseppe a; Corrado, Egle a; Mule, Maria Cristina a; Augugliaro, Stefano a; Cucchiara, Angela b; Novo, Giuseppina a; Amoroso, Gisella a; Assennato, Pasquale a; Hoffmann, Enrico a; Vitale, Francesco b; Novo, Salvatore a
Coronary Artery Disease.
20(3):225-229, May 2009.
(Format: HTML, PDF)
Background: The N-terminal portion of brain natriuretic peptide (NT-proBNP) has been identified as an indicator of prognosis in different cardiovascular diseases. The objective of this study was to determine the utility of measuring plasma NT-proBNP levels in patients with acute coronary syndromes.
Methods and results: We studied 66 patients admitted in our division for acute coronary syndromes. Patients underwent a venous blood sample within 24 h from the admission to determine NT-proBNP levels. Increasing plasma levels of NT-proBNP (in tertiles) was associated with a greater history of hypertension and current smoking, whereas biochemical parameters were associated with higher level of creatine kinase-MB mass, cardiac troponin I, and renal insufficiency. We detected correlations between the values of NT-proBNP and several variables; positive correlations were found between the values of NT-proBNP and creatinine (r= 0354; P=0.0024), cardiac troponin I levels (r=0320; P=0.0111), and creatine kinase-MB mass values (r=0261; P=0.035). An interesting result of our study was a significantly longer hospitalization in those patients belonging to the third tertile compared with those belonging to the first one (P=0.02). Finally, we showed a higher N-terminal brain natriuretic peptide level in patients with poor outcome during the hospitalization (left-ventricular systolic dysfunction, recurrent ischemic events, or death) compared with those who did not (3204 /-1841 vs. 836 /-1136, P=0.003).
Conclusion: Measurement of B-type natriuretic peptide provides predictive information during the hospitalization in patients with acute coronary syndromes.
(C) 2009 Lippincott Williams & Wilkins, Inc.